| Literature DB >> 26157499 |
Heloísa Freiria Tsukamoto1, Viviane de Souza Pinho Costa2, Rubens Alexandre da Silva2, Gislaine Garcia Pelosi3, Luciana Lozza de Moraes Marchiori2, Cláudia Regina Sanches Vaz4, Karen Barros Parron Fernandes5.
Abstract
Introduction Dizziness can be characterized as a balance disorder that causes discomfort, leading to several functional limitations. Currently, vestibular rehabilitation has been highlighted as a possible treatment. Objective Analyze the effects of completing a vestibular rehabilitation treatment protocol on quality of life and postural balance in patients with vestibular complaints, as well as to compare these effects between the patients taking or not taking antivertigo drugs. Methods A nonrandomized controlled trial was performed with 20 patients previously diagnosed with vestibular diseases. Information regarding vertigo symptoms, quality of life as assessed through the Dizziness Handicap Inventory, visual analog scale of dizziness, and stabilometry using force platform was collected. Patients were treated for 12 weeks by a custom protocol. The sample was divided into two groups according to the use (medicated group, n = 9) or not (control group, n = 11) of antivertigo drugs. Results There was improvement in quality of life (p < 0.001) and intensity of dizziness (p = 0.003) with the intervention. An improvement of postural balance was observed through functional tests. However, no statistically significant difference was noted in stabilometry. When both groups were compared, no statistically significant differences between the variations of the variables analyzed were found in the re-evaluation session. Conclusion Quality of life and postural balance are improved with intervention. However, this improvement is not associated with pharmacologic treatment.Entities:
Keywords: dizziness; medicines; postural balance; quality of life; rehabilitation
Year: 2015 PMID: 26157499 PMCID: PMC4490916 DOI: 10.1055/s-0035-1547523
Source DB: PubMed Journal: Int Arch Otorhinolaryngol ISSN: 1809-4864
Fig. 1Participants' selection flowchart.
Baseline clinical data (n = 20)
| Measure | Categories | Absolute frequency ( | Relative frequency (%) |
|---|---|---|---|
| Gender | Female | 19 | 95 |
| Male | 1 | 5 | |
| Age (y) | 20–40 | 2 | 10 |
| 41–60 | 7 | 35 | |
| 61–80 | 9 | 45 | |
| >80 | 2 | 10 | |
| Time of clinical evolution (y) | <1 | 7 | 35 |
| 1–10 | 10 | 50 | |
| 10–20 | 1 | 5 | |
| >20 | 2 | 10 | |
| Main complaint | Dizziness | 10 | 50 |
| Dizziness and tinnitus | 4 | 20 | |
| Dizziness and heavy head | 6 | 30 | |
| Period of dizziness | Anytime | 12 | 60 |
| Morning/afternoon | 5 | 25 | |
| Evening/dawn | 3 | 15 | |
| Periodicity of dizziness | Daily | 12 | 60 |
| Weekly | 4 | 20 | |
| Monthly/sporadic | 4 | 20 | |
| Duration of dizziness | Seconds/minutes | 9 | 45 |
| Hours/days | 11 | 55 | |
| Characteristics of dizziness | Unbalance | 7 | 35 |
| Vertigo | 5 | 25 | |
| Unbalance and vertigo | 5 | 25 | |
| Unbalance and obscured vision | 3 | 15 | |
| Associated symptoms | Yes | 19 | 95 |
| No | 1 | 5 |
Comparison of clinical and functional parameters evaluated before and after the intervention (n = 20)
| Test | Baseline | Posttreatment (12 wk) | |||||
|---|---|---|---|---|---|---|---|
| Median | 1° q | 3° q | Median | 1° q | 3° q |
| |
| DHI total | 41.0 | 27.0 | 58.5 | 17.0 | 10.5 | 37.0 | <0.001 |
| DHI physical aspects | 18.0 | 14.0 | 21.5 | 9.0 | 4.5 | 15.5 | 0.001 |
| DHI functional aspects | 18.0 | 10.0 | 22.0 | 8.0 | 4.5 | 15.5 | 0.004 |
| DHI emotional aspects | 10.0 | 4.0 | 17.0 | 4.0 | 0.5 | 7.5 | 0.001 |
| VAS of dizziness | 4.0 | 2.00 | 6.00 | 1.0 | 0.25 | 3.0 | 0.003 |
| TUG (s) | 6.45 | 5.85 | 7.57 | 5.68 | 5.34 | 6.53 | 0.010 |
| FRT (cm) | 31.31 | 24.98 | 32.39 | 33.79 | 29.70 | 37.24 | 0.010 |
| Single leg stance test EO (s) | 30.00 | 14.62 | 30.00 | 30.00 | 26.25 | 30.00 | 0.028 |
| Single leg stance test EC (s) | 6.84 | 3.00 | 11.37 | 8.44 | 4.12 | 14.91 | 0.034 |
Abbreviations: 1° q, first quartile (25%); 3° q, third quartile (75%); DHI, Dizziness Handicap Inventory; EC, eyes closed; EO, eyes open; FRT, Functional Reach test; TUG, Timed Up and Go test; VAS, visual analog scale.
p < 0.05.
Classification of vestibular dysfunction by DHI in baseline and posttreatment
| Baseline | Posttreatment (12 wk) | |||
|---|---|---|---|---|
| Slight | Moderate | Severe | Total | |
| Slight | 7 | 0 | 0 | 7 |
| Moderate | 4 | 3 | 0 | 7 |
| Severe | 4 | 1 | 1 | 6 |
| Total | 15 | 4 | 1 | 20 |
Abbreviation: DHI, Dizziness Handicap Inventory.
Comparison of stabilometric parameters evaluated before and after intervention (n = 20)
| Test | Baseline | Posttreatment (12 wk) | |||||
|---|---|---|---|---|---|---|---|
| Median | 1°q | 3° q | Median | 1° q | 3° q |
| |
| BEO | |||||||
| COP (cm2) | 1.30 | 0.80 | 3.83 | 1.21 | 0.91 | 2.10 | 0.41 |
| VEL A/P (cm/s) | 0.83 | 0.64 | 1.20 | 0.76 | 0.66 | 0.95 | 0.36 |
| VEL M/L (cm/s) | 0.61 | 0.50 | 0.75 | 0.58 | 0.51 | 0.72 | 0.51 |
| AMP A/P (cm) | 1.97 | 1.40 | 2.98 | 1.78 | 1.29 | 2.08 | 0.03 |
| AMP M/L (cm) | 1.09 | 0.77 | 2.10 | 1.18 | 0.82 | 1.45 | 0.94 |
| FM A/P (Hz) | 0.34 | 0.24 | 0.51 | 0.32 | 0.24 | 0.49 | 0.92 |
| FM M/L (Hz) | 0.38 | 0.27 | 0.60 | 0.50 | 0.33 | 0.53 | 0.39 |
| BHR | |||||||
| COP (cm2) | 2.90 | 1.73 | 5.47 | 3.10 | 1.70 | 4.60 | 0.85 |
| VEL A/P (cm/s) | 1.16 | 0.96 | 1.49 | 1.10 | 0.91 | 1.32 | 0.26 |
| VEL M/L (cm/s) | 0.90 | 0.69 | 1.13 | 0.86 | 0.75 | 0.98 | 0.52 |
| AMP A/P (cm) | 2.17 | 1.99 | 3.38 | 2.39 | 1.96 | 2.80 | 0.43 |
| AMP M/L (cm) | 1.95 | 1.17 | 2.17 | 1.87 | 1.51 | 2.39 | 0.88 |
| FM A/P (Hz) | 0.43 | 0.33 | 0.51 | 0.48 | 0.35 | 0.57 | 0.12 |
| FM M/L (Hz) | 0.44 | 0.32 | 0.54 | 0.41 | 0.36 | 0.49 | 0.50 |
| STEO | |||||||
| COP (cm2) | 4.24 | 3.11 | 7.13 | 3.07 | 2.21 | 5.42 | 0.13 |
| VEL A/P (cm/s) | 1.43 | 1.19 | 1.84 | 1.31 | 1.14 | 1.52 | 0.76 |
| VEL M/L (cm/s) | 1.26 | 1.14 | 1.48 | 1.22 | 1.11 | 1.37 | 0.95 |
| AMP A/P (cm) | 2.53 | 2.26 | 3.52 | 2.24 | 1.84 | 2.73 | 0.04 |
| AMP M/L (cm) | 2.90 | 2.36 | 3.52 | 2.78 | 2.28 | 3.04 | 0.38 |
| FM A/P (Hz) | 0.55 | 0.46 | 0.67 | 0.61 | 0.57 | 0.68 | 0.07 |
| FM M/L (Hz) | 0.40 | 0.37 | 0.46 | 0.42 | 0.38 | 0.50 | 0.46 |
| STEC | |||||||
| COP (cm2) | 6.99 | 3.80 | 13.10 | 4.99 | 3.69 | 8.16 | 0.23 |
| VEL A/P (cm/s) | 2.00 | 1.62 | 2.80 | 1.79 | 1.51 | 2.58 | >0.99 |
| VEL M/L (cm/s) | 1.80 | 1.54 | 2.52 | 1.88 | 1.70 | 2.38 | 0.21 |
| AMP A/P (cm) | 3.40 | 2.42 | 4.67 | 2.70 | 2.32 | 3.81 | 0.11 |
| AMP M/L (cm) | 3.84 | 3.01 | 4.74 | 3.42 | 2.89 | 4.45 | 0.26 |
| FM A/P (Hz) | 0.63 | 0.45 | 0.75 | 0.60 | 0.52 | 0.79 | 0.62 |
| FM M/L (Hz) | 0.48 | 0.39 | 0.52 | 0.48 | 0.41 | 0.60 | 0.06 |
Abbreviations: 1° q, first quartile (25%); 3° q, third quartile (75%); A/P, anteroposterior; AMP, amplitude; BEO, bipedal support with eyes open; BHR, bipedal support with head rotation; COP, pressure center area; FM, average frequency; M/L, medial-lateral; STEC, semi-tandem position with eyes closed; STEO, semi-tandem position with eyes open; VEL, average speed.
p < 0.05.